Mangoceuticals

MGRX

Market cap $22.8M

Overview Fund Activity

2.16 USD

-0.09

4%

At close Updated Sep 17, 4:00 PM EDT

Pre-market

After hours

2.10

-0.06

2.78%

1 day

-4%

5 days

-0.46%

1 month

37.58%

3 months

11.34%

6 months

-40.66%

Year to date

-13.25%

1 year

-41.78%

5 years

-96.4%

10 years

-96.4%

About: Mangoceuticals Inc focuses on developing, marketing, and selling a variety of men's wellness products and services through a telemedicine platform. The company's platform provides access for customers to a licensed pharmacy for online fulfillment and distribution of certain medications that may be prescribed as part of telehealth consultations, including Mango ED products.

Healthcare Health Information Services

0

Funds holding %

of 7,463 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

200% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 1

199% more capital invested

Capital invested by funds: $147K [Q1] → $440K (+$293K) [Q2]

50% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 2

13% more funds holding

Funds holding: 8 [Q1] → 9 (+1) [Q2]

1.17% more ownership

Funds ownership: 1.46% [Q1] → 2.62% (+1.17%) [Q2]

See Fund Rankings

Financial journalist opinion

Mangoceuticals' Patented MGX-0024 Delivers 100% Respiratory Survival in Poultry Studies Signaling Strong Potential Defense Against Spread of Avian Flu

Dallas, TX, May 27, 2025 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) ("Mangoceuticals" or the "Company"), a company focused on developing, marketing, and selling a variety of health and wellness products via a secure telemedicine platform under the brands MangoRx and PeachesRx, and a pioneer in innovative wellness solutions, is excited to share groundbreaking results from field studies based on its patented antiviral compound which it refers to as “MGX-0024”. The field studies were conducted by Solice International at Duraiswamy Farm in Palladam, Tamil Nadu, India. These studies, targeting respiratory diseases in chickens, like Newcastle Disease and Chronic Respiratory Disease (CRD), showed MGX-0024, delivered through drinking water, achieved 100% survival against respiratory illnesses in a large-scale trial, offering a promising solution for poultry health and avian flu defense.

Mangoceuticals' Patented MGX-0024 Delivers 100% Respiratory Survival in Poultry Studies Signaling Strong Potential Defense Against Spread of Avian Flu

ArcStone Securities and Investments Corp. Publishes Industry Report on The Rapid Expansion of The Oral Stimulant Pouch Market

New York, New York, Dallas, Texas, and Toronto, Ontario--(Newsfile Corp. - April 28, 2025) - ArcStone Securities and Investments Corp. ("ArcStone"), a leading cross-border financial services firm, today announced the publication of an industry report on the rapidly emerging oral stimulant pouch market — a multi-billion dollar, high-growth vertical within the health and wellness consumer sector. In the report, ArcStone highlights Mangoceuticals, Inc. (NASDAQ: MGRX) ("Mangoceuticals") following two transformative transactions: Acquisition of the North American rights to Diabetinol, expanding its health and wellness product pipeline; and Acquisition of selective executives, IP, and assets of Smokeless Technology Corp., establishing a leadership position in the oral stimulant pouch market Mangoceuticals, Inc. is strategically positioned to capitalize on this expansion by leveraging its proprietary science, IP portfolio, and product rights to target large addressable markets including energy, mood enhancement, weight loss, diabetes management, and more.

ArcStone Securities and Investments Corp. Publishes Industry Report on The Rapid Expansion of The Oral Stimulant Pouch Market

CORRECTION FROM SOURCE: ArcStone Securities and Investments Corp. Serves as Exclusive Financial Advisor to Mangoceuticals Inc. (MGRX) on its Transformative Acquisition of IP Assets of Smokeless Technology Corp. Marking its Entry into the High Growth Oral Stimulant Pouch Sector

Transaction Marks ArcStone's Continued Cross-Border M&A Franchise Involving a NASDAQ-Listed Company, Underscoring the Strength of Its Global Platform and Financial Acumen In the news release, "ArcStone Securities and Investments Corp. serves as exclusive financial advisor to Mangoceuticals Inc." issued on 25-Apr-2025 by ArcStone over Newsfile, the company has advised that the main heading should not have included "acquisition of Smokeless Technology Corp." The complete, corrected release follows: Transaction Adds Executive Bench Strength, IP and Launches New Business Vertical for Mangoceuticals in Lucrative Oral Stimulant Pouch Segment on the Heels of the Significant Success of Turning Point Brands and Philip Morris International New York, New York and Dallas, Texas--(Newsfile Corp. - April 26, 2025) - ArcStone Securities and Investments Corp. ("ArcStone"), a cross-border financial services firm, is pleased to announce its role as exclusive financial advisor to Mangoceuticals Inc. (NASDAQ: MGRX) ("Mangoceuticals") in its acquisition of IP, assets and technology from Smokeless Technology Corp. ("Smokeless Tech"), a Canadian-based innovator and disruptor in stimulant-based pouches and functional wellness delivery systems. This transaction marks ArcStone's strategic M&A advisory expertise advising a NASDAQ-listed acquirer and a privately held international company, underscoring the strength of its cross-border platform and domain expertise in health and wellness categories.

CORRECTION FROM SOURCE: ArcStone Securities and Investments Corp. Serves as Exclusive Financial Advisor to Mangoceuticals Inc. (MGRX) on its Transformative Acquisition of IP Assets of Smokeless Technology Corp. Marking its Entry into the High Growth Oral Stimulant Pouch Sector

ArcStone Securities and Investments Corp. Serves as Exclusive Financial Advisor to Mangoceuticals Inc. (MGRX) on its Transformative Acquisition of Smokeless Technology Corp. Marking its Entry into the High Growth Oral Stimulant Pouch Sector

Transaction Marks ArcStone's Continued Cross-Border M&A Franchise Involving a NASDAQ-Listed Company, Underscoring the Strength of Its Global Platform and Financial Acumen Transaction Adds Executive Bench Strength, IP and Launches New Business Vertical for Mangoceuticals in Lucrative Oral Stimulant Pouch Segment on the Heels of the Significant Success of Turning Point Brands and Philip Morris International New York, New York, Dallas, Texas and Toronto, Ontario--(Newsfile Corp. - April 25, 2025) - ArcStone Securities and Investments Corp. ("ArcStone"), a cross-border financial services firm, is pleased to announce its role as exclusive financial advisor to Mangoceuticals Inc. (NASDAQ: MGRX) ("Mangoceuticals") in its acquisition of IP, assets and technology from Smokeless Technology Corp. ("Smokeless Tech"), a Canadian-based innovator and disruptor in stimulant-based pouches and functional wellness delivery systems. This transaction marks ArcStone's strategic M&A advisory expertise advising a NASDAQ-listed acquirer and a privately held international company, underscoring the strength of its cross-border platform and domain expertise in health and wellness categories.

ArcStone Securities and Investments Corp. Serves as Exclusive Financial Advisor to Mangoceuticals Inc. (MGRX) on its Transformative Acquisition of Smokeless Technology Corp. Marking its Entry into the High Growth Oral Stimulant Pouch Sector

Mangoceuticals Announces Strategic Entry into High Growth Pouch Industry Through Acquisition of Smokeless Technology IP and Appointment of Tim Corkum Ex Philip Morris Executive to Lead High Growth Pouch Division

DALLAS, TX, April 25, 2025 (GLOBE NEWSWIRE) -- Mangoceuticals Inc. (NASDAQ: MGRX) (“Mangoceuticals” or “MGRX”), a company focused on developing, marketing, and selling a variety of health and wellness products via a secure telemedicine platform under the brands MangoRx and PeachesRx, is pleased to announce that it has entered into an Intellectual Property Purchase Agreement to acquire all intellectual property, product formulations, know-how, distribution, supplier relationships and related assets of Smokeless Technology Corp. (“Smokeless Tech”), a Canadian-based pouch innovation company specializing in stimulant and functional pouches.

Mangoceuticals Announces Strategic Entry into High Growth Pouch Industry Through Acquisition of Smokeless Technology IP and Appointment of Tim Corkum Ex Philip Morris Executive to Lead High Growth Pouch Division

CEO Spotlight: How Mangoceuticals Inc. is Reinventing The Personal Health Landscape

DALLAS, TX / ACCESS Newswire / April 22, 2025 / Mangoceuticals Inc. (NASDAQ:MGRX) is on a mission to rewrite the playbook for men's performance, health, and vitality. Its pursuit comes at a time when opportunities have become enormous, with patent expirations on several of the world's most popular health and wellness drugs, opening vast pathways to exploit segmented market opportunities, each worth billions.

CEO Spotlight: How Mangoceuticals Inc. is Reinventing The Personal Health Landscape

Mangoceuticals, Inc. Executes Exclusive Distribution Agreement with Propre Energie for Clinically Proven Dermytol®️ Skincare Treatment Targeting Hyperpigmentation

Dallas, TX & Quebec, Canada, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX), a company focused on developing, marketing, and selling a variety of men's wellness products and services via a secure telemedicine platform, is pleased to announce that it has entered into an exclusive Master Distribution Agreement with Propre Energie, Inc., the developer of skincare brand Dermytol®, a clinically proven treatment designed to improve skin tone and reduce hyperpigmentation.

Mangoceuticals, Inc. Executes Exclusive Distribution Agreement with Propre Energie for Clinically Proven Dermytol®️ Skincare Treatment Targeting Hyperpigmentation

Mangoceuticals, Inc. Completes Acquisition of Mushroom-Based Wellness and Innovations Patent

Dallas, TX, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling men's health and wellness products via a secure telemedicine platform, today announced the acquisition of patent number WO 2023/086647 PCT/US2022/049857, for mushroom-derived compositions and methods of treatment. This new addition to MangoRx's intellectual property portfolio highlights the Company's commitment to innovative solutions that support holistic health and wellness.

Mangoceuticals, Inc. Completes Acquisition of Mushroom-Based Wellness and Innovations Patent

MangoRx Responds to and Refutes Recent Claims Made by Eli Lilly

Dallas, Texas, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling men's health and wellness products via a secure telemedicine platform learned earlier this morning that Eli Lilly has made certain public claims alleging, and has stated that it has filed a lawsuit against MangoRx claiming, that MangoRx improperly copied its weight-loss medicine, Zepbound and Mounjaro. MangoRx strongly refutes any and all claims made by Eli Lilly regarding the sale of compounded tirzepatide. MangoRx believes it has strong arguments against Eli Lilly's claims and intends to vigorously defend itself in this matter.

MangoRx Responds to and Refutes Recent Claims Made by Eli Lilly

Mangoceuticals, Inc. Announces Participation at the Centurion One Capital 2nd Annual Bahamas Summit 2024

Dallas, Texas--(Newsfile Corp. - October 18, 2024) - Mangoceuticals, Inc. (NASDAQ: MGRX), a company focused on developing, marketing, and selling men's health and wellness products via a secure telemedicine platform,, is pleased to announce it will be presenting at the Centurion One Capital 2nd Annual Bahamas Summit, which will be taking place at the exclusive Rosewood Baha Mar Hotel from Tuesday, October 22nd to Wednesday, October 23rd, 2024, in Nassau, Bahamas. Jacob Cohen, Founder and CEO, is scheduled to present on Wednesday, October 23rd at 11:10 EDT.

Mangoceuticals, Inc. Announces Participation at the Centurion One Capital 2nd Annual Bahamas Summit 2024

See News Rankings

Charts implemented using Lightweight Charts™